LEADS BIOLABS Aktie

 

NANJING, China, May 28, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the Phase II clinical study of its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), in combination with......

NANJING, China, May 18, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has received approval from the Center for Drug Evaluation......

NANJING, China, May 11, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) successfully held its R&D Symposium in Shanghai. Under the theme "Leads Innovation, Future Forward", the event comprehensively presented the Company's strategic elevation......

NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has selected Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (known as DNTH212 outside Greater China)....

NANJING, China, April 21, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the first patient has been successfully dosed in a phase Ⅱ clinical study evaluating Opamtistomig (LBL-024), the company's core investigational PD-L1/4-1BB bispecific antibody, for the first-line treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma....

CNE100003F19 CNE100003FC4 CNE100003FF7 CNE100003FL5 CNE100003K53 CNE100003KK7 CNE100003PH2 CNE1000040M1 CNE100004JD2 CNE1000055Z1 CNE1000057K9 CNE100005RV4 CNE100006624 CNE1000069Z2 CNE100006JG0 CNE100006M66 CNE100006N08 CNE100006NF4 CNE100006NX7 CNE100006QK7 CNE100006S86 CNE100006T02 CNE100006V73 CNE100006Z61 CNE100006Z79 CNE1000070H8 CNE1000070L0 CNE1000076P8 CNE100007C18 CNE100007CV2 CNE100007DG1 CNE100007DW8 CNE100007F07 CNE100007F72 CNE100007F98 CY0103562118 DE000A0N3UD5 DE000A351SC5 DK0060817898 DK0061026119 DK0061078425 DK0061123312 DK0061407699 DK0061408580 DK0061411964 DK0061417144 DK0061536828 DK0061675006 DK0061805660 DK0063855085 HK0000120151 HK0000504214 HK0000527306 HK0000544194 HK0000709128 HK0000735800 HK0000827664 HK0000981941 HK0014000126 HK0345001611 HK0521001989 HK0560006634 HK0836012952 ID1000058407 ID1000074008 ID1000094204 ID1000097207 ID1000100209 ID1000110000 ID1000118300 ID1000125107 ID1000125909 ID1000165004...

Unterbrechnung des Handels von im Spezialistenmodell der Fortlaufenden Auktion gehandelten Wertpapieren. Aufgrund technischer Probleme wird der Handel in den unten benannten, vom Quoteverpflichteten MWBMU (MWB FAIRTRADE WERTPAPIERHANDELSBANK AG) betreuten Wertpapieren unterbrochen. Bestehende Orders werden nicht geloescht. Sollten Sie Rueckfragen haben, wenden Sie sich bitte an Cash Markets Operations unter der Telefonnummer +49-69-211-11400 SG1CH4000003 GB00BNXM3P96 US52678P2056 SE0015809967 CNE100001QS1 PLDBENR00017 CNE1000070H8 US55406W1036 KYG1117K1141 CA7660871004 AU0000318552 CNE100006NX7 FR0013333077 GB0001110096 IE00BJ5FQX74 US25432X1028 CA5179071017 CA49804N1042 PLSTIGR00012 AU0000026122 JP3172060000 CA29764L1085 PLA346100011 CA2523711091 US78518H2022 KYG2159E1070 GB00BFPM8908 PLCRFRG00016 GB00BNVVGD77 KYG011251066 US12763L1052 AU0000012056 SE0015961404 AU0000426512 SE0017072267 JP3856000009 US28852N3070 AU0000165375 AU0000028367 CA4637731015 US09254V1...